ANDA 210043, held by Amneal Pharmaceuticals. Methylprednisolone Acetate.
As of Nov 21, 2026, ANDA 210043 (Methylprednisolone Acetate), held by Amneal Pharmaceuticals, was first approved by FDA on May 20, 2019, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Methylprednisolone Acetate40MG/ML ยท injectable;injection | Methylprednisolone Acetate | Rx |
| Methylprednisolone Acetate80MG/ML ยท injectable;injection | Methylprednisolone Acetate | Rx |
| Oct 15, 2024 | Supplement 36Labeling ยท Standard review | Approved | None posted |
| May 7, 2024 | Supplement 32Labeling ยท Standard review | Approved | None posted |
| May 7, 2024 | Supplement 33Labeling ยท Standard review | Approved | None posted |
| Sep 12, 2023 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Sep 12, 2023 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters